<DOC>
	<DOCNO>NCT02329080</DOCNO>
	<brief_summary>This open , non comparative , multicentre phase II trial , evaluate efficacy feasibility new sequential combination HD-MTX-AraC-based chemoimmunotherapy , follow R-ICE regimen , high-dose chemotherapy support ASCT .</brief_summary>
	<brief_title>New Combination Chemoimmunotherapy Systemic B-cell Lymphoma With Central Nervous System Involvement</brief_title>
	<detailed_description>Treatment include 6 course chemoimmunotherapy , first three course high dose methotrexate-based combination ( MATRIX ) follow three course R-ICE combination finally BCNU-thiotepa- contain condition subsequent autologous stem cell transplantation . MATRIX ( course 1 , 2 , 3 ) : Rituximab 375 mg/m2 , Methotrexate 3.5 g/m2 , Cytarabine 2 g/m2 , Folinic rescue 15 mg/m2 , Thiotepa 30 mg/m2 , Intrathecal liposomial cytarabine 50 mg , rHuG-CSF 2,5 g/kg s.c. R-ICE ( course 4 , 5 , 6 ) : Rituximab 375 mg/m2 , Etoposide 100 mg/m2/d , Ifosfamide 5 g/m2 , Intrathecal liposomial cytarabine 50 mg</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>1 . Histologically confirm diagnosis diffuse large Bcell lymphoma 2 . CNS involvement ( brain , meninges , cranial nerve , eye and/or spinal cord ) diagnosis ( concomitant extraCNS disease ) relapse conventional chemo ( immuno ) therapy 3 . Diagnosis CNS involvement either brain biopsy CSF cytology examination . Neuroimaging alone acceptable stereotactic biopsy formally contraindicated disease previously histologically document area CNS localization concomitant diffuse progression systemic disease . 4 . No previous treatment highdose methotrexatebased chemotherapy and/or brain irradiation . Onetwo course RCHOP combination upfront therapy admit patient large amount and/or extensive extraCNS disease could condition prognosis early phase treatment . Local investigator decide initial RCHOP need base patient 's condition 5 . Age 1870 year 6 . ECOG performance status 03 7 . Adequate bone marrow ( Platelets count ≥100.000/mm3 , hemoglobin ≥9 g/dL , neutrophil count≥1.500/mm3 ) , renal ( creatinine clearance ≥60 mL/min ) , cardiac ( LVEF ≥50 % ) , hepatic function ( total serum bilirubine ≤3 mg/dL , AST/ALT GGT ≤2.5 per upper normal limit value ) , unless abnormality due lymphoma infiltration 8 . Absence HIV infection detectable HCVRNA and/or HBsAg and/or HBVDNA 9 . No concurrent malignancy . Previous malignancy accept surgically cure evidence disease last 3 year regular followup 10 . Absence familial , sociological geographical condition potentially hamper compliance study protocol followup schedule 11 . Female patient must nonpregnant nonlactating . Sexually active patient childbearing potential must implement adequate contraceptive measure study participation 12 . No treatment experimental drug within 6 week previous enrolment 13 . Given write informed consent prior study specific procedure , understand patient right withdraw study time , without prejudice . Informed consent sign patient 's guardian acceptable patient able decide inclusion study due cognitive impairment 1 . Other lymphoma category diffuse large Bcell lymphoma . In particular , patient primary mediastinal lymphoma , intravascular large Bcell lymphoma legtype large Bcell lymphoma exclude . 2 . Patients positive flow cytometry examination CSF , negative result CSF conventional cytology , without evidence CNS disease . 3 . Patients exclusive CNS disease presentation ( primary CNS lymphoma ) exclude 4 . Previous treatment support autologous allogeneic stem cells/bone marrow transplantation . 5 . Symptomatic coronary artery disease , cardiac arrhythmia well control medication myocardial infarction within last 6 month ( New York Heart Association Class III IV heart disease ) 6 . Any serious medical condition could impair ability patient participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>